Lee, Kyonggi-Do
Byoung Min Lee, Kyonggi-Do KR
Patent application number | Description | Published |
---|---|---|
20110003148 | PROCESS FOR PRODUCING CELLULOSE MULTI-FILAMENT WITH LOWER COEFFICIENT OF VARIATION OF SECTION DIAMETER - The present invention relates to a cellulose fiber having a highly homogeneous section, particularly to a cellulose fiber with lower Coefficient of Variation of section diameter (CV(%)). Specifically, the present invention relates to a cellulose fiber wherein Coefficient of Variation of section diameter (CV(%)) of a mono-filament constituting a multi-filament prepared by dissolving a cellulose powder in liquid N-methylmorpholine N-oxide (hereinafter referred to “NMMO”) is below 2.5. According to the present invention, a lyocell multi-filament is produced comprising the steps of (i) preparing a spinning solution by homogeneously dispersing, swelling and dissolving cellulose powder in a NMMO solution; (ii) spinning the spinning solution into an air gap through a spinning nozzle; and (iii) coagulating the extruded-spun spinning solution in a coagulation bath. In particular, the coagulating step is adjusted by means of a coagulation coefficient in the range of 0.8 to 1.3 and the coagulation coefficient is expressed as T | 01-06-2011 |
Ho-Jeong Lee, Kyonggi-Do KR
Patent application number | Description | Published |
---|---|---|
20090311224 | THERAPEUTIC AGENT COMPRISING LIPOCALIN 2 AGAINST CANCER METASTASIS, AND METHODS OF EARLY DIAGNOSIS AND INHIBITION OF CANCER METASTASIS USING LIPOCALIN 2 - The present invention relates to a pharmaceutical composition for the inhibition of cancer metastasis, more precisely, a novel pharmaceutical composition against cancer metastasis comprising lipocalin 2 protein, a gene encoding the protein, an expression vector containing the gene or cells transfected with the expression vector as an effective ingredient, a method for the inhibition of cancer metastasis using the composition, a diagnostic kit for the prediction of cancer metastasis, a method for the selection of a metastasis risk group using the kit, a novel pharmaceutical composition for the inhibition of cancer growth and a method for the inhibition of cancer growth using the same. The pharmaceutical composition of the present invention specifically inhibits cancer metastasis, so that it can improve the effect of cancer treatment dramatically. And, the diagnostic kit and the method for the selection of a metastasis risk group using the kit enable the selection of a metastasis risk group by measuring the level of lipocalin 2 in tumor tissues or in body fluid. Therefore, the kit and the method can contribute to the effective clinical control of a cancer patient. Further, the composition of the invention can be effectively used for the treatment of liver cancer owing to its liver cancer growth inhibitory effect. | 12-17-2009 |
Kong-Ju Lee, Kyonggi-Do KR
Patent application number | Description | Published |
---|---|---|
20090311224 | THERAPEUTIC AGENT COMPRISING LIPOCALIN 2 AGAINST CANCER METASTASIS, AND METHODS OF EARLY DIAGNOSIS AND INHIBITION OF CANCER METASTASIS USING LIPOCALIN 2 - The present invention relates to a pharmaceutical composition for the inhibition of cancer metastasis, more precisely, a novel pharmaceutical composition against cancer metastasis comprising lipocalin 2 protein, a gene encoding the protein, an expression vector containing the gene or cells transfected with the expression vector as an effective ingredient, a method for the inhibition of cancer metastasis using the composition, a diagnostic kit for the prediction of cancer metastasis, a method for the selection of a metastasis risk group using the kit, a novel pharmaceutical composition for the inhibition of cancer growth and a method for the inhibition of cancer growth using the same. The pharmaceutical composition of the present invention specifically inhibits cancer metastasis, so that it can improve the effect of cancer treatment dramatically. And, the diagnostic kit and the method for the selection of a metastasis risk group using the kit enable the selection of a metastasis risk group by measuring the level of lipocalin 2 in tumor tissues or in body fluid. Therefore, the kit and the method can contribute to the effective clinical control of a cancer patient. Further, the composition of the invention can be effectively used for the treatment of liver cancer owing to its liver cancer growth inhibitory effect. | 12-17-2009 |
Kook-Heui Lee, Kyonggi-Do KR
Patent application number | Description | Published |
---|---|---|
20140321351 | METHOD OF TRANSMITTING/RECEIVING CONTROL MESSAGE IN A MOBILE COMMUNICATION SYSTEM PROVIDING MULTIMEDIA BROADCAST/MULTICAST SERVICE - A method and apparatus are provided for providing a multimedia broadcast/multicast service (MBMS) to a user equipment (UE) by a base station in a mobile communication system. The method includes transmitting, to the UE, a first message including information about a scheduling period and an offset indicating a start point of the scheduling period; transmitting, to the UE, a second message including information about at least one MBMS in the scheduling period, based on the information about the scheduling period and the offset; and transmitting, to the UE, data of the at least one MBMS via an MBMS radio bearer (RB) established for the at least one MBMS. The information about the at least one MBMS includes identification of the at least one MBMS. | 10-30-2014 |
Kyung-Hee Lee, Kyonggi-Do KR
Patent application number | Description | Published |
---|---|---|
20100004466 | Benzothiophen-2-carbonylguanidine derivatives, preparation thereof, and pharmaceutical composition containing the same - The present invention is related to benzothiophen-2-carbonylguanidine derivatives, a preparation method thereof, and pharmaceutical compositions containing the same. The derivatives have potent inhibitory effect on the sodium/hydrogen exchanger NHE-I, improve the functional recovery of ischemia/reperfusion-induced heart injury in isolated ischemic heart models, and significantly reduce the myocardiac infarct size in in vivo ischemic animal models, thereby showing excellent cardioprotective effects. Also, the derivatives are protective of both neuronal cells and the brain as proven by their protective effects on neuronal cells from necrosis and apoptosis and by their ability to significantly reduce cerebral infarct sizes in in vivo ischemic brain models. The derivatives can be effectively used for the prevention and treatment of ischemic heart diseases such as myocardiac infarction, arrhythmia, angina pectoris and the like, and cerebrovascular diseases such as cerebral stroke and be used as cardioprotective agents to the patients undergoing reperfusion therapy including chemicals such as thrombolytic agents, or surgery such as coronary artery bypass and percutaneous transluminal coronary angioplasty. | 01-07-2010 |
Seo-Hem Lee, Kyonggi-Do KR
Patent application number | Description | Published |
---|---|---|
20100002296 | CIRCULAR POLARIZER COMPOSITE AND AN OPTICAL SYSTEM COMPRISING THE SAME - A circular polarizer composite including a plane polarizer, a first quarter-wavelength retarder, a cholesteric liquid crystal (CLC) film and a second quarter-wavelength retarder, wherein optical axes of the first quarter-wavelength retarder and the second quarter-wavelength retarder are perpendicularly crossed to each other. Also disclosed is an optical system including the circular polarizer composite and an emissive display module. | 01-07-2010 |
Seo-Hern Lee, Kyonggi-Do KR
Patent application number | Description | Published |
---|---|---|
20090303589 | OPTICAL FILM COMPOSITE FOR BRIGHTNESS ENHANCEMENT INCLUDING A BIREFRINGENT POLYMER LAYER - The present invention provides an optical film composite that comprises a linear, reflective polarizing film; a first polymeric substrate layer having birefringence, which is placed on the reflective polarizing film; and a second polymeric substrate layer placed beneath the reflective polarizing film, wherein the optical axis of the first polymeric substrate layer is oriented with respect to the transmission axis of the reflective polarizing film to have of 0° to 25° of an angular difference between the axes. The optical film composite can be employed in LCD devices to improve optical performance. | 12-10-2009 |
20110261584 | SYSTEMS AND METHODS FOR CONTROLLING BACKLIGHT OUTPUT CHARACTERISTICS - A backlight includes a light source and one or more light recycling films. The light source generates light that exits the light source with an angular exit distribution. The light recycling films are oriented in relation to the light source so that the prism peaks of the recycling films are oriented away from the light source. The recycling films have a range of optimal incident angles that allow light to pass through the recycling films without recycling. The components of the light source, the characteristics of the recycling films, or both, are configured to control the overlap between the exit distribution of the light source and the optimal incident angle range of the recycling films. | 10-27-2011 |
20130335823 | Optical Film Stack - Optical film stacks are disclosed. The optical film stacks can include a first reflective polarizer, a second reflective polarizer, and a retardance layer disposed between the first reflective polarizer and the second reflective polarizer. | 12-19-2013 |
Seung Hoo Lee, Kyonggi-Do KR
Patent application number | Description | Published |
---|---|---|
20090287755 | SEQUENCE SIMILARITY MEASURING APPARATUS AND CONTROL METHOD THEREOF - Disclosed is a sequence similarity measuring apparatus and a method of controlling the same. The sequence similarity measuring apparatus using dynamic programming includes: a matrix generating unit for generating a matrix based on the dynamic programming by using two sequences; a normalization unit for calculating a similarity reference value by inputting an element value of a last row/column of the matrix generated by the matrix generating unit into a normalization formula for a given sequence length; and a similarity measuring unit for measuring predefined sequence similarity between the two sequences, based on the similarity reference value calculated by the normalization unit. This makes it possible to easily and correctly achieve similarity comparison between multiple sequences, and thus this technology is expected to be widely utilized in biology/programming application fields. | 11-19-2009 |
Tae Jung Lee, Kyonggi-Do KR
Patent application number | Description | Published |
---|---|---|
20090011234 | Cellulose Multi-Filament - The present invention relates to cellulose fiber containing 500 to 2000 of filaments and having homogeneous physical properties and the multi-filaments according to the present invention is characterized in that the strength and the breaking elongation of the multi-filaments are 4 to 9 g/d and 4 to 15%, respectively. In particular, the present invention is characterized in that each mono-filament selected 100 strands from every three part divided from multi-filaments has properties as following: (a) 3 to 9 g/d in average strength, 7 to 15% in average breaking elongation and 0.035 to 0.055 in by birefringence, (b) the differences of the above three parts are below 1.0 g/d in average strength, 1.5% in breaking elongation and 0.7 denier in denier, (c) the CV (%) (coefficient of variation) of the above three parts are below 10%, and (d) the birefringence differences of the above three parts are below 0.004. | 01-08-2009 |
20090288748 | Cellulose raw cord for rubber reinforcement - The present invention provides a lyocell raw cord prepared from at least 2-ply lyocell multifilaments, which gives a stress-strain curve exhibiting that (a) the lyocell raw cord has an elongation of 1.5% or less at an initial stress of 1.0 g/d, and an initial modulus value of 50 to 100 g/d; (b) has an elongation of 7% or less in a stress region of 1.0 g/d to 4.0 g/d; and (c) has an elongation of 1% or more at a tensile strength of 4.0 g/d to the breaking point, as measured in the dried state. | 11-26-2009 |
20110003148 | PROCESS FOR PRODUCING CELLULOSE MULTI-FILAMENT WITH LOWER COEFFICIENT OF VARIATION OF SECTION DIAMETER - The present invention relates to a cellulose fiber having a highly homogeneous section, particularly to a cellulose fiber with lower Coefficient of Variation of section diameter (CV(%)). Specifically, the present invention relates to a cellulose fiber wherein Coefficient of Variation of section diameter (CV(%)) of a mono-filament constituting a multi-filament prepared by dissolving a cellulose powder in liquid N-methylmorpholine N-oxide (hereinafter referred to “NMMO”) is below 2.5. According to the present invention, a lyocell multi-filament is produced comprising the steps of (i) preparing a spinning solution by homogeneously dispersing, swelling and dissolving cellulose powder in a NMMO solution; (ii) spinning the spinning solution into an air gap through a spinning nozzle; and (iii) coagulating the extruded-spun spinning solution in a coagulation bath. In particular, the coagulating step is adjusted by means of a coagulation coefficient in the range of 0.8 to 1.3 and the coagulation coefficient is expressed as T | 01-06-2011 |
Yong Oh Lee, Kyonggi-Do KR
Patent application number | Description | Published |
---|---|---|
20100004466 | Benzothiophen-2-carbonylguanidine derivatives, preparation thereof, and pharmaceutical composition containing the same - The present invention is related to benzothiophen-2-carbonylguanidine derivatives, a preparation method thereof, and pharmaceutical compositions containing the same. The derivatives have potent inhibitory effect on the sodium/hydrogen exchanger NHE-I, improve the functional recovery of ischemia/reperfusion-induced heart injury in isolated ischemic heart models, and significantly reduce the myocardiac infarct size in in vivo ischemic animal models, thereby showing excellent cardioprotective effects. Also, the derivatives are protective of both neuronal cells and the brain as proven by their protective effects on neuronal cells from necrosis and apoptosis and by their ability to significantly reduce cerebral infarct sizes in in vivo ischemic brain models. The derivatives can be effectively used for the prevention and treatment of ischemic heart diseases such as myocardiac infarction, arrhythmia, angina pectoris and the like, and cerebrovascular diseases such as cerebral stroke and be used as cardioprotective agents to the patients undergoing reperfusion therapy including chemicals such as thrombolytic agents, or surgery such as coronary artery bypass and percutaneous transluminal coronary angioplasty. | 01-07-2010 |